An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals

Vaccine

Volumn 26, Issue 33, 2008, Pages 4262-4266

  Hewetson, John F ^a,b   Little, Stephen F ^a   Ivins, Bruce E ^a   Johnson, Wendy M ^a   Pittman, Phillip R ^a   Brown, J Edward ^a   Norris, Sarah L ^a,b   Nielsen, Carl J ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Goldbelt Raven LLC   (United States)

Author keywords

Anthrax; AVA; Passive protection; Vaccine

Indexed keywords

ANTHRAX VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LD 50; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SURVIVAL RATE; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; FEMALE; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; MICE; NEUTRALIZATION TESTS; STATISTICS AS TOPIC; SURVIVAL ANALYSIS;

EID: 47149083995     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.068     Document Type: Article

References (28)

1. Welkos S.L., and Friedlander A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb Pathogen 5 2 (1988) 127-139
2. Ivins B.E., Fellows P.F., and Nelson G.O. Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine 12 10 (1994) 872-874
3. Little S.F., and Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun 52 2 (1986) 509-512
4. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., and Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 52 2 (1986) 356-363
5. Zaucha G.M., Pitt M.L.M., Estep J., Ivins B.E., and Friendlander A.M. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122 11 (1998) 982-992
6. Pitt M.L.M., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 32 (2001) 4768-4773
7. Little S.F., Ivins B.E., Webster W.M., Fellows P.F., Pitt M.L.M., Norris S.L.W., et al. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24 14 (2006) 2530-2536
8. Williamson E.D., Hodgson I., Walker N.J., Topping A.W., Duchars M.G., Mott J.M., et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 73 9 (2005) 5978-5987
9. Friedlander A.M., Welkos S.L., Pitt M.L., Ezzell J.W., Worsham P.L., Rose K.J., et al. Post-exposure prophylaxis against experimental inhalation anthrax. J Infect Dis 167 5 (1993) 1239-1243
10. Ivins B.E., Pitt M.L., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16 11-12 (1998) 1141-1148
11. Pitt M.L., Little S., Ivins B.E., Fellows P., Boles J., Barth J., et al. In vitro correlation of immunity in an animal model of inhalational anthrax. J Appl Microbiol 87 2 (1999) 304
12. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 3-4 (2004) 422-430
13. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 5 (2001) 2888-2893
14. Peachman K.K., Rao M., Alving C.R., Burge R., Leppla S.H., Rao V.B., et al. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infect Immun 74 1 (2006) 794-797
15. Weiss S., Kobiler D., Levy H., Marcus H., Pass A., Rothschild N., et al. Immunological correlates for protection against Intranasal challenge on Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun 74 1 (2006) 394-398
16. Welkos S.L., Keener T.J., and Gibbs P.H. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 51 3 (1986) 795-800
17. Brossier F., Mock M., and Sirard J.C. Antigen delivery by attenuated Bacillus anthracis: new prospects in veterinary vaccines. J Appl Microbiol 87 2 (1999) 298-302
18. Beedham R.J., and Turnbull P.C.B. Williamson ED Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19 (2001) 4409-4416
19. Loving C.L., Kennett M., Lee G.M., Grippe V.K., and Merkel T.J. Murine aerosol challenge model of anthrax. Infect Immun 75 6 (2007) 2689-2698
20. Pittman P.R., Norris S.L., Barrera-Oro J.G., Bedwell D., Cannon T.L., and McKee Jr. K.T. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24 17 (2006) 3654-3660
21. Semenova V.A., Steward-Clark E., Stamy K.L., Taylor T.H., Schmidt D.S., Martin S.K., et al. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol 11 5 (2004) 919-923
22. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 8 10 (2002) 1103-1110
23. Hering D., Thompson W., Hewetson J., Little S., Norris S., and Pace-Templeton J. Validation of the anthrax lethal toxin neutralization assay. Biologicals 32 1 (2004) 17-27
24. Pittman P.R., Kim-Ahn G., Pifat D.Y., Coonan K., Gibbs P., Little S., et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20 9-10 (2002) 1412-1420
25. Diehl K.H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., et al. A Good Practice Guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21 1 (2001) 15-23
26. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blind, controlled, multicenter trial. Vaccine 24 33-34 (2006) 5950-5959
27. Campbell J.D., Clement K.H., Wasserman S.S., Donegan S., Chrisley L., and Kotloff K.L. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Human Vaccines 3 5 (2007) 205-211
28. Rynkiewicz D, Ransom J, Sim I, Giri L, Rathkopf M, Quinn J, et al. Marked enhancement of antibody response to BioThrax™ anthrax vaccine with CPG 7909 in healthy adult volunteers. Am Soc Microbiol Ann Mtg (2005) [I.C.A.A.C., Washington, DC Abs. Final Program LB 25].